Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at Needham & Company
August 5, 2021 6:30 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "ACAD reported $115.2M in 2Q21 Nuplazid sales, below our $130.0M and consensus $126.3M ests. Sales +vely impacted by volume... More
